Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (415)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (328)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 61 to 70 of 427
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Breast cancer guidelines
NICE guideline
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
28 January 2025
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)
Technology appraisal guidance
10 September 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
29 January 2025
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Technology appraisal guidance
TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Technology appraisal guidance
5 March 2025
Previous page
1
…
5
6
Current page
7
8
9
…
43
Page
7
of
43
Next page
Results per page
10
25
50
All
Back to top